{"filing":{"accession_number":"0001087294-26-000053","cik":"0001087294","ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"cpix-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000053/cpix-20260624.htm"},"events":[{"id":13989,"run_id":12438,"accession_number":"0001087294-26-000053","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This is a disclosure of shareholder vote results at a special meeting held on June 24, 2026, where shareholders approved a proposal to authorize and approve a strategic transaction with Apotex involving the sale of Cumberland's FDA-approved commercial products and related assets under an Asset Purchase Agreement. The filing explicitly reports voting tallies (10,492,455 for, 15,904 against, 1,267 abstentions) and quorum information, which is the core content of Item 5.07. While the underlying transaction is material M\u0026A activity, the 8-K Item 5.07 section itself is reporting the vote results, making shareholder_vote_results the appropriate classification.","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11293,"accession_number":"0001087294-26-000053","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a disclosure of shareholder vote results at a special meeting held on June 24, 2026, where shareholders approved a proposal to authorize and approve a strategic transaction with Apotex involving the sale of Cumberland's FDA-approved commercial products and related assets under an Asset Purchase Agreement. The filing explicitly reports voting tallies (10,492,455 for, 15,904 against, 1,267 abstentions) and quorum information, which is the core content of Item 5.07. While the underlying transaction is material M\u0026A activity, the 8-K Item 5.07 section itself is reporting the vote results, making shareholder_vote_results the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:17.856949+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11293,"accession_number":"0001087294-26-000053","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a disclosure of shareholder vote results at a special meeting held on June 24, 2026, where shareholders approved a proposal to authorize and approve a strategic transaction with Apotex involving the sale of Cumberland's FDA-approved commercial products and related assets under an Asset Purchase Agreement. The filing explicitly reports voting tallies (10,492,455 for, 15,904 against, 1,267 abstentions) and quorum information, which is the core content of Item 5.07. While the underlying transaction is material M\u0026A activity, the 8-K Item 5.07 section itself is reporting the vote results, making shareholder_vote_results the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:02:17.856949+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-06-25"}]}